Inflammation in the CNS: Understanding Various Aspects of the Pathogenesis of Alzheimer's Disease

Alzheimer’s disease is a progressive and deadly neurodegenerative disorder and one of the most common causes of dementia globally. Current, insufficiently sensitive and specific methods of early diagnosing and monitoring this disease prompt a search for new tools. Numerous literature data have indicated that the pathogenesis of Alzheimer’s disease (AD) is not limited to the neuronal compartment but involves various immunological mechanisms. Neuroinflammation has been recognized as a very important process in AD pathology. It seems to play pleiotropic roles, both neuroprotective and neurodegenerative, in the development of cognitive impairment depending on the stage of the disease. Mounting evidence demonstrates that inflammatory proteins could be considered biomarkers of disease progression. Therefore, the present review summarizes the role of some inflammatory molecules and their potential utility in detecting and monitoring dementia severity. This paper also provides a valuable insight into new mechanisms leading to the development of dementia, which might be useful in discovering possible anti-inflammatory treatment.

[1]  E. Solito,et al.  The Impact of Ageing on the CNS Immune Response in Alzheimer’s Disease , 2021, Frontiers in Immunology.

[2]  P. Scheltens,et al.  Aducanumab: Appropriate Use Recommendations , 2021, The Journal of Prevention of Alzheimer's Disease.

[3]  M. Eriksdotter,et al.  Cerebrospinal fluid inflammatory markers in Alzheimer's disease: influence of comorbidities. , 2021, Current Alzheimer Research.

[4]  M. Memo,et al.  A Conformation Variant of p53 Combined with Machine Learning Identifies Alzheimer Disease in Preclinical and Prodromal Stages , 2020, Journal of personalized medicine.

[5]  D. Baltriukienė,et al.  The Microbiota–Gut–Brain Axis and Alzheimer’s Disease: Neuroinflammation Is to Blame? , 2020, Nutrients.

[6]  A. Słowik,et al.  Cerebrospinal Fluid and Blood CX3CL1 as a Potential Biomarker in Early Diagnosis and Prognosis of Dementia. , 2020, Current Alzheimer research.

[7]  G. Nunnari,et al.  Postsynaptic damage and microglial activation in AD patients could be linked CXCR4/CXCL12 expression levels , 2020, Brain Research.

[8]  A. Cianciulli,et al.  The Regulatory Role of IL-10 in Neurodegenerative Diseases , 2020, Biomolecules.

[9]  I. Lindberg,et al.  A comprehensive systematic review of CSF proteins and peptides that define Alzheimer’s disease , 2020, Clinical Proteomics.

[10]  M. O’Banion,et al.  Evaluating the Effect of Interleukin-4 in the 3xTg Mouse Model of Alzheimer’s Disease , 2020, Frontiers in Neuroscience.

[11]  D. Hadjipavlou-Litina,et al.  Curcumin in Health and Diseases: Alzheimer’s Disease and Curcumin Analogues, Derivatives, and Hybrids , 2020, International journal of molecular sciences.

[12]  I. Mook‐Jung,et al.  Peripheral inflammatory biomarkers in Alzheimer’s disease: a brief review , 2019, BMB reports.

[13]  T. Ozben,et al.  Neuro-inflammation and anti-inflammatory treatment options for Alzheimer's disease. , 2019, Clinical biochemistry.

[14]  I. Mook‐Jung,et al.  Transfer of a healthy microbiota reduces amyloid and tau pathology in an Alzheimer’s disease animal model , 2019, Gut.

[15]  F. Trousse,et al.  Knockdown of the CXCL12/CXCR7 chemokine pathway results in learning deficits and neural progenitor maturation impairment in mice , 2019, Brain, Behavior, and Immunity.

[16]  M. Nguyen,et al.  Metal Ions in Alzheimer's Disease: A Key Role or Not? , 2019, Accounts of chemical research.

[17]  Dongfang Zhang,et al.  Natural products as a potential modulator of microglial polarization in neurodegenerative diseases. , 2019, Pharmacological research.

[18]  J. Palha,et al.  Proinflammatory and anti-inflammatory cytokines in the CSF of patients with Alzheimer's disease and their correlation with cognitive decline , 2019, Neurobiology of Aging.

[19]  D. Y. Lee,et al.  Blood acetylcholinesterase level is a potential biomarker for the early detection of cerebral amyloid deposition in cognitively normal individuals , 2019, Neurobiology of Aging.

[20]  Jeffrey L. Cummings,et al.  Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options , 2019, Journal of Alzheimer's disease : JAD.

[21]  L. Tan,et al.  Inflammatory markers in Alzheimer’s disease and mild cognitive impairment: a meta-analysis and systematic review of 170 studies , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

[22]  A. Mulak,et al.  Brain-Gut-Microbiota Axis in Alzheimer’s Disease , 2019, Journal of neurogastroenterology and motility.

[23]  A. Angiolillo,et al.  Circulating levels of IL-1 family cytokines and receptors in Alzheimer’s disease: new markers of disease progression? , 2018, Journal of Neuroinflammation.

[24]  J. Wiltfang,et al.  Glycoprotein NMB: a novel Alzheimer’s disease associated marker expressed in a subset of activated microglia , 2018, Acta Neuropathologica Communications.

[25]  R. Petersen,et al.  The Cross-Sectional and Longitudinal Associations Between IL-6, IL-10, and TNFα and Cognitive Outcomes in the Mayo Clinic Study of Aging. , 2018, The journals of gerontology. Series A, Biological sciences and medical sciences.

[26]  B. Garner,et al.  Understanding the Role of ApoE Fragments in Alzheimer’s Disease , 2018, Neurochemical Research.

[27]  J. Kamińska,et al.  CXCL9, CXCL10, CXCL11, and their receptor (CXCR3) in neuroinflammation and neurodegeneration. , 2018, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

[28]  C. Luis,et al.  Plasma cytokine IL‐6 levels and subjective cognitive decline: preliminary findings , 2018, International journal of geriatric psychiatry.

[29]  Alan J. Thomas,et al.  Peripheral inflammation in prodromal Alzheimer’s and Lewy body dementias , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[30]  Matthew R Chapman,et al.  The role of microbial amyloid in neurodegeneration , 2017, PLoS pathogens.

[31]  I. Ferrer,et al.  YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias , 2017, Molecular Neurodegeneration.

[32]  A. Bush,et al.  Evidence that iron accelerates Alzheimer’s pathology: a CSF biomarker study , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[33]  A. Carvalho,et al.  Peripheral inflammatory markers in Alzheimer’s disease: a systematic review and meta-analysis of 175 studies , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[34]  M. Fakhoury Microglia and Astrocytes in Alzheimer's Disease: Implications for Therapy , 2017, Current neuropharmacology.

[35]  Karsten Melcher,et al.  Amyloid beta: structure, biology and structure-based therapeutic development , 2017, Acta Pharmacologica Sinica.

[36]  J. Clarimón,et al.  YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer’s disease and other tauopathies , 2017, Journal of Neuroinflammation.

[37]  M. Gallego,et al.  Musicoterapia en la enfermedad de Alzheimer: efectos cognitivos, psicológicos y conductuales , 2017 .

[38]  G. Rossi,et al.  Microbiota modulation counteracts Alzheimer’s disease progression influencing neuronal proteolysis and gut hormones plasma levels , 2017, Scientific Reports.

[39]  S. Georgopoulos,et al.  Peripheral Tumor Necrosis Factor-Alpha (TNF-α) Modulates Amyloid Pathology by Regulating Blood-Derived Immune Cells and Glial Response in the Brain of AD/TNF Transgenic Mice , 2017, The Journal of Neuroscience.

[40]  Kyong Hwan Jin,et al.  Predicting cognitive decline with deep learning of brain metabolism and amyloid imaging , 2017, Behavioural Brain Research.

[41]  Paul Edison,et al.  An early and late peak in microglial activation in Alzheimer’s disease trajectory , 2017, Brain : a journal of neurology.

[42]  Matheus Roriz‐Cruz,et al.  Cerebrospinal fluid inflammatory markers in amnestic mild cognitive impairment , 2017, Geriatrics & gerontology international.

[43]  G. Frisoni,et al.  Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly , 2017, Neurobiology of Aging.

[44]  M. Heneka,et al.  Danger‐associated molecular patterns in Alzheimer’s disease , 2017, Journal of leukocyte biology.

[45]  Debomoy K Lahiri,et al.  Targeting Tumor Necrosis Factor Alpha for Alzheimer's Disease. , 2016, Current Alzheimer research.

[46]  Zhijun Zhang,et al.  Inflammatory Cytokines and Alzheimer’s Disease: A Review from the Perspective of Genetic Polymorphisms , 2016, Neuroscience Bulletin.

[47]  Xinwen Zhou,et al.  The dual roles of cytokines in Alzheimer’s disease: update on interleukins, TNF-α, TGF-β and IFN-γ , 2016, Translational Neurodegeneration.

[48]  K. Blennow,et al.  sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers , 2016, EMBO molecular medicine.

[49]  W. Le,et al.  Differential Roles of M1 and M2 Microglia in Neurodegenerative Diseases , 2016, Molecular Neurobiology.

[50]  A. Fagan,et al.  Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status , 2016, Acta Neuropathologica.

[51]  M. Ciebiada,et al.  Adiponectin, leptin and IL-1 β in elderly diabetic patients with mild cognitive impairment , 2015, Metabolic Brain Disease.

[52]  B. Stevens,et al.  Microglia Function in Central Nervous System Development and Plasticity. , 2015, Cold Spring Harbor perspectives in biology.

[53]  D. Catalucci,et al.  Neutrophils promote Alzheimer's disease–like pathology and cognitive decline via LFA-1 integrin , 2015, Nature Medicine.

[54]  O. Garaschuk,et al.  Neuroinflammation in Alzheimer's disease , 2015, The Lancet Neurology.

[55]  K. Fukunaga,et al.  The extracellular fragment of GPNMB (Glycoprotein nonmelanosoma protein B, osteoactivin) improves memory and increases hippocampal GluA1 levels in mice , 2015, Journal of neurochemistry.

[56]  R. Palmer,et al.  Serum Interleukin (IL)-15 as a Biomarker of Alzheimer's Disease , 2015, PloS one.

[57]  Y. Lee,et al.  Association between TNF-α promoter −308 A/G polymorphism and Alzheimer’s disease: a meta-analysis , 2015, Neurological Sciences.

[58]  G. Taglialatela,et al.  NFκB-Activated Astroglial Release of Complement C3 Compromises Neuronal Morphology and Function Associated with Alzheimer’s Disease , 2015, Neuron.

[59]  Meiping Zhu,et al.  Neuroinflammation in Alzheimer's disease: chemokines produced by astrocytes and chemokine receptors. , 2014, International journal of clinical and experimental pathology.

[60]  B. Baune,et al.  Inflammasomes in neuroinflammation and changes in brain function: a focused review , 2014, Front. Neurosci..

[61]  M. Heneka,et al.  Body Fluid Cytokine Levels in Mild Cognitive Impairment and Alzheimer’s Disease: a Comparative Overview , 2014, Molecular Neurobiology.

[62]  Y. Hattori,et al.  Synthesis and evaluation of curcumin derivatives toward an inhibitor of beta-site amyloid precursor protein cleaving enzyme 1. , 2014, Bioorganic & medicinal chemistry letters.

[63]  Bradley T. Hyman,et al.  Alzheimer’s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta , 2013, Neuron.

[64]  H. Gendelman,et al.  CCL2 affects β-amyloidosis and progressive neurocognitive dysfunction in a mouse model of Alzheimer's disease , 2013, Neurobiology of Aging.

[65]  H. Lashuel Molecular mechanisms for neurodegeneration , 2013 .

[66]  Cornelia M. Wilson,et al.  Tau protein kinases: Involvement in Alzheimer's disease , 2013, Ageing Research Reviews.

[67]  J. Trojanowski,et al.  Synthetic Tau Fibrils Mediate Transmission of Neurofibrillary Tangles in a Transgenic Mouse Model of Alzheimer's-Like Tauopathy , 2013, The Journal of Neuroscience.

[68]  A. Quintana,et al.  Interleukin-6, a Major Cytokine in the Central Nervous System , 2012, International journal of biological sciences.

[69]  K. Cain,et al.  Higher Plasma Fractalkine Is Associated With Better 6-Month Outcome From Ischemic Stroke , 2012, Stroke.

[70]  Zhi-Qin Xi,et al.  Altered expression of CX3CL1 in patients with epilepsy and in a rat model. , 2012, The American journal of pathology.

[71]  K. Kawahara,et al.  Intracerebral microinjection of interleukin-4/interleukin-13 reduces β-amyloid accumulation in the ipsilateral side and improves cognitive deficits in young amyloid precursor protein 23 mice , 2012, Neuroscience.

[72]  Yun-wu Zhang,et al.  CutA Divalent Cation Tolerance Homolog (Escherichia coli) (CUTA) Regulates β-Cleavage of β-Amyloid Precursor Protein (APP) through Interacting with β-Site APP Cleaving Protein 1 (BACE1)* , 2012, The Journal of Biological Chemistry.

[73]  Mark E. Schmidt,et al.  The Alzheimer’s Disease Neuroimaging Initiative: A review of papers published since its inception , 2012, Alzheimer's & Dementia.

[74]  Oskar Hansson,et al.  CCL2 Is Associated with a Faster Rate of Cognitive Decline during Early Stages of Alzheimer's Disease , 2012, PloS one.

[75]  W. Griffin Alzheimer's - Looking beyond plaques , 2011, F1000 medicine reports.

[76]  T. Kiyota,et al.  AAV serotype 2/1-mediated gene delivery of anti-inflammatory interleukin-10 enhances neurogenesis and cognitive function in APP+PS1 mice , 2011, Gene Therapy.

[77]  P. Caramelli,et al.  Chemokines in CSF of Alzheimer's disease patients. , 2011, Arquivos de neuro-psiquiatria.

[78]  B. Ray,et al.  Oxidative insults to neurons and synapse are prevented by aged garlic extract and S‐allyl‐l‐cysteine treatment in the neuronal culture and APP‐Tg mouse model , 2011, Journal of neurochemistry.

[79]  Chengjie Xiong,et al.  YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease , 2010, Biological Psychiatry.

[80]  A. Orekhov,et al.  The effects of time-released garlic powder tablets on multifunctional cardiovascular risk in patients with coronary artery disease , 2010, Lipids in Health and Disease.

[81]  R. Ransohoff,et al.  Regulation of Tau Pathology by the Microglial Fractalkine Receptor , 2010, Neuron.

[82]  M. Megna,et al.  Cytokine polymorphisms and Alzheimer disease: possible associations , 2010, Neurological Sciences.

[83]  김경욱,et al.  구강편평상피암종에서 stromal cell-derived factor-1의 발현 , 2010 .

[84]  B. Ray,et al.  Neuroinflammation in Alzheimer's disease: different molecular targets and potential therapeutic agents including curcumin. , 2009, Current opinion in pharmacology.

[85]  G. Halliday,et al.  Monocyte Chemoattractant Protein‐1 Plays a Dominant Role in the Chronic Inflammation Observed in Alzheimer's Disease , 2009, Brain pathology.

[86]  Xudong Huang,et al.  Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative diseases. , 2009, Biochimica et biophysica acta.

[87]  S. Amini,et al.  Monocyte chemoattractant protein-1 (MCP-1): an overview. , 2009, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[88]  L. Lue,et al.  Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer's brain is mediated by the JNK-AP1 signaling pathway , 2009, Neurobiology of Disease.

[89]  V. Perry,et al.  Microglial physiology: unique stimuli, specialized responses. , 2009, Annual review of immunology.

[90]  C. Sen,et al.  Neuroprotective and antiinflammatory properties of a novel demethylated curcuminoid. , 2009, Antioxidants & redox signaling.

[91]  I. Bechmann,et al.  TREM2 is upregulated in amyloid plaque‐associated microglia in aged APP23 transgenic mice , 2008, Glia.

[92]  Jae Woong Lee,et al.  Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation , 2008, Journal of Neuroinflammation.

[93]  F. Sánchez-García,et al.  Cytokine IL‐1 beta but not IL‐1 alpha promoter polymorphism is associated with Alzheimer disease in a population from the Canary Islands, Spain , 2008, European journal of neurology.

[94]  F. Schmidt Meta-Analysis , 2008 .

[95]  Veer Bala Gupta,et al.  Anti-amyloidogenic activity of S-allyl-l-cysteine and its activity to destabilize Alzheimer's β-amyloid fibrils in vitro , 2007, Neuroscience Letters.

[96]  R. Hendrickson,et al.  Molecular Biomarkers , 2007 .

[97]  R. Petersen,et al.  Alzheimer's disease and mild cognitive impairment. , 2007, Neurologic clinics.

[98]  N. Chauhan,et al.  Effect of aged garlic extract on APP processing and tau phosphorylation in Alzheimer's transgenic model Tg2576. , 2006, Journal of ethnopharmacology.

[99]  C. Colton,et al.  Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD , 2006, Journal of Neuroinflammation.

[100]  A. Rombos,et al.  IL-15 Is Elevated in Cerebrospinal Fluid of Patients With Alzheimer’s Disease and Frontotemporal Dementia , 2006, Journal of geriatric psychiatry and neurology.

[101]  R. Mrak,et al.  Glia and their cytokines in progression of neurodegeneration , 2005, Neurobiology of Aging.

[102]  B. Michel,et al.  Oxidative Stress Level in Circulating Neutrophils Is Linked to Neurodegenerative Diseases , 2004, Journal of Clinical Immunology.

[103]  R. Maccioni,et al.  Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. , 2004, Experimental cell research.

[104]  D. Gambi,et al.  IL-4 in vitro production is upregulated in Alzheimer's disease patients treated with acetylcholinesterase inhibitors , 2004, Experimental Gerontology.

[105]  I. Romero,et al.  Regulation of chemokine receptor expression in human microglia and astrocytes , 2003, Journal of Neuroimmunology.

[106]  R. Mrak,et al.  Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer's disease: potential significance for tau protein phosphorylation , 2001, Neurochemistry International.

[107]  W. Liao,et al.  Inflammation in Alzheimer's Disease , 1999, Science.

[108]  S. Dinsmore Treatment options for Alzheimer's disease , 1999, The Journal of the American Osteopathic Association.

[109]  R. Bronson,et al.  Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[110]  S. Itohara,et al.  Protective Roles of γδ T Cells and Interleukin-15 in Escherichia coli Infection in Mice , 1998, Infection and Immunity.

[111]  T. Springer,et al.  Functional expression of the CXC-chemokine receptor-4/fusin on mouse microglial cells and astrocytes. , 1997, Journal of immunology.

[112]  Peter Riederer,et al.  Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients , 1995, Neuroscience Letters.

[113]  G. Forloni,et al.  Reciprocal control of inflammatory cytokines, IL-1 and IL-6, and β-amyloid production in cultures , 1995, Neuroscience Letters.

[114]  J. Parker,et al.  Amyloid deposition in Alzheimer's disease. , 1993, Annals of clinical and laboratory science.

[115]  L. Altstiel,et al.  Cytokines in Alzheimer's disease , 1991, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[116]  C. Figdor,et al.  Interleukin-4 (IL-4) inhibits secretion of IL-1 beta, tumor necrosis factor alpha, and IL-6 by human monocytes. , 1990, Blood.

[117]  J. Satoh,et al.  Microglia express GPNMB in the brains of Alzheimer's disease and Nasu-Hakola disease. , 2019, Intractable & rare diseases research.

[118]  K. Laskowska,et al.  A Comparative Analysis of the Treatment of Decision-Making by or for Patients with Neurodegenerative Diseases in Four Legal Jurisdictions. , 2019, Journal of Alzheimer's disease : JAD.

[119]  M. Heneka,et al.  Microglia in Neurodegenerative Disorders. , 2019, Methods in molecular biology.

[120]  R. Nitsch,et al.  Neurodegenerative Diseases , 2018, Springer International Publishing.

[121]  D. Haas Biomarker for Alzheimer's Disease , 2018 .

[122]  A. Akaike,et al.  PE859, A Novel Curcumin Derivative, Inhibits Amyloid-β and Tau Aggregation, and Ameliorates Cognitive Dysfunction in Senescence-Accelerated Mouse Prone 8. , 2017, Journal of Alzheimer's disease : JAD.

[123]  B. Miller,et al.  Amnestic mild cognitive impairment , 2017 .

[124]  F. Russo,et al.  Music and Memory in Alzheimer's Disease and The Potential Underlying Mechanisms. , 2016, Journal of Alzheimer's disease : JAD.

[125]  C. Nicholson,et al.  Clearance systems in the brain-implications for Alzheimer disease. , 2015, Nature reviews. Neurology.

[126]  Xuying Liu,et al.  Design, synthesis and anti-Alzheimer properties of dimethylaminomethyl-substituted curcumin derivatives. , 2014, Bioorganic & Medicinal Chemistry Letters.

[127]  L. Bertram,et al.  TREM 2 and Neurodegenerative Disease , 2013 .

[128]  Federal de Sergipe Cytokine Gene Polymorphisms and Alzheimer's Disease in Brazil , 2013 .

[129]  T. Wyss-Coray,et al.  Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. , 2012, Cold Spring Harbor perspectives in medicine.

[130]  D. Selkoe Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[131]  C. Laske,et al.  Decreased CXCL12 (SDF-1) plasma levels in early Alzheimer's disease: a contribution to a deficient hematopoietic brain support? , 2008, Journal of Alzheimer's disease : JAD.

[132]  B. Snyder Music and memory , 2000 .

[133]  S. Itohara,et al.  Protective roles of gamma delta T cells and interleukin-15 in Escherichia coli infection in mice. , 1998, Infection and immunity.

[134]  X. Bao Beta-amyloid protein and Alzheimer's disease. , 1996, Chinese Medical Journal.